Cargando…
Patient Protection in Clinical Trials in India: Some Concerns
Clinical trial participants should not be influenced by undue inducement. Clinical trial investigators should be guided by ethical principles, and patient protection should be a top priority. This does not seem to be the case in India.
Autor principal: | Srinivasan, Sandhya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications Pvt Ltd
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146073/ https://www.ncbi.nlm.nih.gov/pubmed/21814629 |
Ejemplares similares
-
A critical appraisal of clinical trials conducted and subsequent drug approvals in India and South Africa
por: Limaye, Dnyanesh, et al.
Publicado: (2015) -
Human Subject Protection In India – Is It Adequate?
por: Mahaluxmivala, Narges
Publicado: (2010) -
Consent concerns in clinical trials of investigational therapies for COVID-19: Vulnerability versus voluntariness
por: Bhatt, Arun
Publicado: (2020) -
Ethics committees in India: Facing the challenges!
por: Kadam, Rashmi, et al.
Publicado: (2012) -
Dissemination of trial results to participants in phase III pragmatic clinical trials: an audit of trial investigators intentions
por: Raza, M Zulfiqar, et al.
Publicado: (2020)